[breadcrumb_custom]

Are Revance Therapeutics Inc (NASDAQ: RVNC) Shares Worth Your Money In 2024?

In the latest trading session, 0.47 million Revance Therapeutics Inc (NASDAQ:RVNC) shares changed hands as the company’s beta touched 1.02. With the company’s most recent per share price at $5.91 changing hands around $0.0 or -0.08% at last look, the market valuation stands at $518.52M. RVNC’s current price is a discount, trading about -542.64% off its 52-week high of $37.98. The share price had its 52-week low at $5.00, which suggests the last value was 15.4% up since then. When we look at Revance Therapeutics Inc’s average trading volume, we note the 10-day average is 1.63 million shares, with the 3-month average coming to 1.24.

Revance Therapeutics Inc (NASDAQ:RVNC) trade information

Instantly RVNC was in red as seen in intraday trades today. With action 15.78%, the performance over the past five days has been green. The drop to weekly highs of 6.03 subtracted -0.08% to the stock’s daily price. The company’s shares are showing year-to-date downside of -32.82%, with the 5-day performance at 15.78% in the green. However, in the 30-day time frame, Revance Therapeutics Inc (NASDAQ:RVNC) is -6.42% down. Looking at the short shares, we see there were 12.65 million shares sold at short interest cover period of 7.47 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Revance Therapeutics Inc (RVNC) estimates and forecasts

Data shows that the Revance Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -68.77% over the past 6 months, a 19.18% in annual growth rate that is considerably higher than the industry average of 15.50%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Revance Therapeutics Inc will rise 60.40%, while the growth in revenue is estimated to hit 17.60% for the next quarter. Year-over-year growth is forecast to reach 71.10% up from the last financial year.

Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of $62.63 million. 8 analysts are of the opinion that Revance Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $61.2 million. The company’s revenue for the corresponding quarters a year ago was $49.92 million and $49.33 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 25.50%. The estimates for the next quarter sales put growth at 24.10%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -4.10%. The 2024 estimates are for Revance Therapeutics Inc earnings to increase by 17.25%, but the outlook for the next 5-year period is at 11.60% per year.

On Key

Related Posts